Phaseline

Companies › Savara

Savara: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Regramostim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 3Autoimmune Pulmonary Alveolar ProteinosisMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04544293RegramostimPhase 3Autoimmune Pulmonary Alveolar ProteinosisImmunologyMay 2027
NCT06431776RegramostimPhase 3Autoimmune Pulmonary Alveolar ProteinosisImmunologyJun 2027

From the company's SEC filings

Cash and short-term investments of $130m on 2026-09-30; operating cash outflow about $141m a year; runway about 11 months at that burn, to Aug 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CSF3R (1)

Companies with the same targets

Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Spectrum Pharmaceuticals Qilu Pharmaceutical Kexing Biopharm Yaqrit

Companies built like this

Alumis Quoin Pharmaceuticals Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.